[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618446":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":17,"centralContacts":17,"locations":23,"responsibleParty":39,"collaborators":17,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":17,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":65,"whyStopped":17,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Shanghai Chest Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dapagliflozin","EXPERIMENTAL","Dapagliflozin 10 mg per day for 3 months after initial catheter ablation",[13],"Drug: Dapagliflozin (10Mg Tab) along with standard medical therapy",{"label":15,"type":16,"description":17,"interventionNames":17},"Control","NO_INTERVENTION",null,[19],{"type":20,"name":21,"description":11,"armGroupLabels":22,"otherNames":17},"DRUG","Dapagliflozin (10Mg Tab) along with standard medical therapy",[9],[24],{"facility":5,"status":17,"city":25,"state":17,"zip":17,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Shanghai","China","CN",{"type":29,"coordinates":30},"Point",[31,32],121.45806,31.22222,{"lat":32,"lon":31},[35],{"name":36,"role":37,"phone":17,"phoneExt":17,"email":38},"Mu Qin, Dr","CONTACT","qinmuae@163.com",{"type":40,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"PRINCIPAL_INVESTIGATOR","Xu Liu","professor","100618446","epicardial-adipose-tissue-targeted-dapagliflozin-for-reducing-electrical-remodeling-in-atrial-fibrillation-100618446",false,"NCT07331727","Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation","Efficacy of Dapagliflozin on Catheter Ablation Outcomes in Persistent Atrial Fibrillation Patients With Increased Epicardial Adipose Tissue","EAT-DARE-AF","Inclusion Criteria:\n\n* Age 18-80 years;\n\nDiagnosis of persistent atrial fibrillation (continuous AF \\>7 days and ≤5 years);\n\nPlanned first-time catheter ablation for AF;\n\nNo class I indications for dapagliflozin, defined as:\n\nNo diabetes mellitus;\n\nNo history of heart failure (HFrEF, HFmrEF, or HFpEF);\n\nNo chronic kidney disease (eGFR ≥60 mL\u002Fmin\u002F1.73 m²);\n\nEvidence of increased epicardial adipose tissue on cardiac CT or cardiac MRI, defined according to pre-specified imaging thresholds;\n\nAbility to provide written informed consent.\n\nExclusion Criteria:\n\n* Duration of persistent AF \\>5 years;\n\nLeft atrial anteroposterior diameter \\>50 mm on transthoracic echocardiography;\n\nPrior AF catheter ablation or surgical ablation;\n\nCurrent or recent (within 3 months) use of any SGLT2 inhibitor;\n\nSevere structural heart disease (e.g., hypertrophic cardiomyopathy, rheumatic valvular disease, dilated cardiomyopathy);\n\nContraindications to catheter ablation (e.g., left atrial thrombus, active infection);\n\nEstimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m²;\n\nType 1 diabetes or history of diabetic ketoacidosis;\n\nPregnancy or breastfeeding;\n\nAny condition deemed by investigators to make study participation inappropriate.","ALL","18 Years","80 Years",{"count":55,"type":56},280,"ESTIMATED","INTERVENTIONAL",[59],"NA","Persistent atrial fibrillation (PeAF) is associated with a high risk of recurrence following catheter ablation despite advances in ablation technology and strategies. Beyond electrophysiological mechanisms, increasing evidence suggests that atrial structural and inflammatory remodeling plays a pivotal role in the initiation and maintenance of AF, particularly in persistent forms.\n\nEpicardial adipose tissue (EAT) is a metabolically active visceral fat depot located between the myocardium and visceral pericardium. EAT shares a common microcirculation with the underlying atrial myocardium and exerts paracrine and vasocrine effects through the secretion of pro-inflammatory cytokines, adipokines, and profibrotic mediators. Increased EAT volume or thickness has been consistently associated with AF burden, atrial fibrosis, left atrial enlargement, and a higher risk of AF recurrence after catheter ablation.\n\nSodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated pleiotropic cardiovascular benefits beyond glucose lowering, including reduction in visceral adiposity, attenuation of systemic and local inflammation, and favorable effects on cardiac remodeling. Observational studies and randomized trials in patients with diabetes or heart failure suggest that SGLT2i therapy reduces incident AF and AF recurrence after ablation. However, the effect of SGLT2i in non-diabetic, non-heart failure patients-particularly those with increased EAT as a distinct pathophysiological substrate-remains unclear.This trial is designed to evaluate whether dapagliflozin, administered peri-ablation, can reduce atrial arrhythmia recurrence in PeAF patients with increased EAT but without class I indications for SGLT2i. This targeted approach aims to provide mechanistic and clinical evidence supporting metabolic-inflammatory modulation as an adjunctive strategy to catheter ablation.",[62],"Atrial Fibrillation (AF)",[64],"Atrial Fibrillation","NOT_YET_RECRUITING","2025-12-29",{"date":68,"type":69},"2026-01-12","ACTUAL",{"date":71,"type":56},"2026-01-01",{"date":73,"type":56},"2026-12-31",{"name":5,"class":6},1]